MX2008014898A - Composicion para el diagnostico de enfermedades relacionadas con amiloides. - Google Patents
Composicion para el diagnostico de enfermedades relacionadas con amiloides.Info
- Publication number
- MX2008014898A MX2008014898A MX2008014898A MX2008014898A MX2008014898A MX 2008014898 A MX2008014898 A MX 2008014898A MX 2008014898 A MX2008014898 A MX 2008014898A MX 2008014898 A MX2008014898 A MX 2008014898A MX 2008014898 A MX2008014898 A MX 2008014898A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- related disease
- amyloid
- brain
- diagnosing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/0429—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K51/0431—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición que comprende un compuesto representado por la fórmula general (I), en donde R1 representa un grupo 5-iodotiofen-2-ilo o semejantes y R2 representa un grupo 4-dimetilaminfenilo o semejantes. Esta composición es de utilidad para el diagnostico de una enfermedad relacionada con amiloides, tal como el mal de Alzheimer, porque el compuesto tiene una gran especificidad de unión por la proteína ß amiloide, una gran permeabilidad a través de la barrera hematoencefálica y la propiedad de ser eliminado rápidamente de sitios distintos de las placas seniles en el cerebro.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006144024 | 2006-05-24 | ||
JP2007081637 | 2007-03-27 | ||
PCT/JP2007/060436 WO2007136059A1 (ja) | 2006-05-24 | 2007-05-22 | アミロイド関連疾患診断のための組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008014898A true MX2008014898A (es) | 2009-04-22 |
Family
ID=38723372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008014898A MX2008014898A (es) | 2006-05-24 | 2007-05-22 | Composicion para el diagnostico de enfermedades relacionadas con amiloides. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20100278733A1 (es) |
EP (1) | EP2030635A1 (es) |
JP (1) | JPWO2007136059A1 (es) |
KR (1) | KR20090048400A (es) |
AU (1) | AU2007252463A1 (es) |
BR (1) | BRPI0712268A2 (es) |
CA (1) | CA2652440A1 (es) |
IL (1) | IL195271A0 (es) |
MX (1) | MX2008014898A (es) |
RU (1) | RU2008150631A (es) |
WO (1) | WO2007136059A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120237446A1 (en) * | 2005-03-25 | 2012-09-20 | Bayer Pharma Aktiengesellschaft | Compounds for binding and imaging amyloid plaques and their use |
WO2010093001A1 (ja) * | 2009-02-13 | 2010-08-19 | 国立大学法人大阪大学 | アルツハイマー病の診断方法および診断薬 |
US10721269B1 (en) | 2009-11-06 | 2020-07-21 | F5 Networks, Inc. | Methods and system for returning requests with javascript for clients before passing a request to a server |
US9141625B1 (en) | 2010-06-22 | 2015-09-22 | F5 Networks, Inc. | Methods for preserving flow state during virtual machine migration and devices thereof |
US9270766B2 (en) | 2011-12-30 | 2016-02-23 | F5 Networks, Inc. | Methods for identifying network traffic characteristics to correlate and manage one or more subsequent flows and devices thereof |
US10230566B1 (en) | 2012-02-17 | 2019-03-12 | F5 Networks, Inc. | Methods for dynamically constructing a service principal name and devices thereof |
EP2853074B1 (en) | 2012-04-27 | 2021-03-24 | F5 Networks, Inc | Methods for optimizing service of content requests and devices thereof |
US10187317B1 (en) | 2013-11-15 | 2019-01-22 | F5 Networks, Inc. | Methods for traffic rate control and devices thereof |
US10834065B1 (en) | 2015-03-31 | 2020-11-10 | F5 Networks, Inc. | Methods for SSL protected NTLM re-authentication and devices thereof |
US11350254B1 (en) | 2015-05-05 | 2022-05-31 | F5, Inc. | Methods for enforcing compliance policies and devices thereof |
US11757946B1 (en) | 2015-12-22 | 2023-09-12 | F5, Inc. | Methods for analyzing network traffic and enforcing network policies and devices thereof |
US10404698B1 (en) | 2016-01-15 | 2019-09-03 | F5 Networks, Inc. | Methods for adaptive organization of web application access points in webtops and devices thereof |
US11178150B1 (en) | 2016-01-20 | 2021-11-16 | F5 Networks, Inc. | Methods for enforcing access control list based on managed application and devices thereof |
US11063758B1 (en) | 2016-11-01 | 2021-07-13 | F5 Networks, Inc. | Methods for facilitating cipher selection and devices thereof |
US10505792B1 (en) | 2016-11-02 | 2019-12-10 | F5 Networks, Inc. | Methods for facilitating network traffic analytics and devices thereof |
US10812266B1 (en) | 2017-03-17 | 2020-10-20 | F5 Networks, Inc. | Methods for managing security tokens based on security violations and devices thereof |
US11122042B1 (en) | 2017-05-12 | 2021-09-14 | F5 Networks, Inc. | Methods for dynamically managing user access control and devices thereof |
US11343237B1 (en) | 2017-05-12 | 2022-05-24 | F5, Inc. | Methods for managing a federated identity environment using security and access control data and devices thereof |
WO2018212368A1 (ko) * | 2017-05-16 | 2018-11-22 | 연세대학교 산학협력단 | 신규 화합물 및 그를 유효성분으로 포함하는 약학 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB929450A (en) * | 1960-10-11 | 1963-06-26 | Ciba Ltd | New thiophenes and process for preparing same |
US5539555A (en) | 1990-07-20 | 1996-07-23 | Displaytech, Inc. | High contrast distorted helex effect electro-optic devices and tight ferroelectric pitch ferroelectric liquid crystal compositions useful therein |
WO2003070951A1 (fr) * | 2002-02-21 | 2003-08-28 | Japan Science And Technology Agency | Gene specifique a l'arteriosclerose et utilisation de ce gene |
JP2004250411A (ja) * | 2003-02-21 | 2004-09-09 | Bf Kenkyusho:Kk | アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物 |
JP2004250407A (ja) * | 2003-02-21 | 2004-09-09 | Bf Kenkyusho:Kk | アミロイド蓄積性疾患の診断プローブおよび治療用化合物 |
EP2433634A3 (en) * | 2004-09-17 | 2012-07-18 | The Whitehead Institute for Biomedical Research | Compounds, compositions and methods of inhibiting a-synuclein toxicity |
JP2007106755A (ja) * | 2005-09-13 | 2007-04-26 | Japan Health Science Foundation | アミロイドイメージング用プローブ |
JP4318677B2 (ja) | 2005-09-13 | 2009-08-26 | シャープ株式会社 | 画像処理装置、プログラム、及び記録媒体 |
-
2007
- 2007-05-22 RU RU2008150631/15A patent/RU2008150631A/ru unknown
- 2007-05-22 EP EP07743870A patent/EP2030635A1/en not_active Withdrawn
- 2007-05-22 JP JP2008516697A patent/JPWO2007136059A1/ja active Pending
- 2007-05-22 CA CA002652440A patent/CA2652440A1/en not_active Abandoned
- 2007-05-22 US US12/301,805 patent/US20100278733A1/en not_active Abandoned
- 2007-05-22 AU AU2007252463A patent/AU2007252463A1/en not_active Abandoned
- 2007-05-22 BR BRPI0712268-3A patent/BRPI0712268A2/pt not_active IP Right Cessation
- 2007-05-22 WO PCT/JP2007/060436 patent/WO2007136059A1/ja active Application Filing
- 2007-05-22 KR KR1020087031265A patent/KR20090048400A/ko not_active Application Discontinuation
- 2007-05-22 MX MX2008014898A patent/MX2008014898A/es active IP Right Grant
-
2008
- 2008-11-13 IL IL195271A patent/IL195271A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2652440A1 (en) | 2007-11-29 |
KR20090048400A (ko) | 2009-05-13 |
WO2007136059A1 (ja) | 2007-11-29 |
JPWO2007136059A1 (ja) | 2009-10-01 |
BRPI0712268A2 (pt) | 2012-01-17 |
AU2007252463A1 (en) | 2007-11-29 |
IL195271A0 (en) | 2011-08-01 |
EP2030635A1 (en) | 2009-03-04 |
US20100278733A1 (en) | 2010-11-04 |
RU2008150631A (ru) | 2010-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2008014898A (es) | Composicion para el diagnostico de enfermedades relacionadas con amiloides. | |
EA200701810A1 (ru) | Производное изоксазолина и новый способ его получения | |
GEP20146046B (en) | Organic compounds | |
MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
MX2007001035A (es) | Metodo para producir una composicion, la composicion y su uso. | |
SI2091948T1 (sl) | Novi inhibitorji glutaminil ciklaze | |
TW200738666A (en) | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | |
ZA200810113B (en) | Method for the treatment and prevention of ocular disorders | |
MX2010004319A (es) | Compuesto de alfa-(n-sulfonamido)acetamida novedoso como un inhibidor de producccion de peptido beta amiloide. | |
WO2008108386A1 (ja) | 医薬組成物 | |
NO20076371L (no) | Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner | |
WO2008070129A3 (en) | Compositions and methods for the treatment of inflammatory disease | |
UA93380C2 (en) | 3,5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission | |
UA86119C2 (ru) | Амидные пролекарства гемцитабина, их композиции и применение | |
WO2008137816A8 (en) | Tricyclic compounds as matrix metalloproteinase inhibitors | |
HK1114840A1 (en) | Malonamide derivatives as inhibitors of gamma-secretase for the treatment of alzheimer's disease | |
NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
TW200702330A (en) | 3,4,5-Substituted piperidines | |
NO20090233L (no) | Ny sammensetning som har affinitet for amyloid | |
IL198089A0 (en) | An alzheimer's disease progression inhibitor containing heterocyclic compound having specific structure | |
WO2009153178A3 (en) | Aryl ketone as mri | |
EA200700360A1 (ru) | Новые производные амида гетероциклической карбоновой кислоты | |
NO20085317L (no) | Imidazoazepinonforbindelser | |
WO2007131907A3 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
DE112006000984A5 (de) | Verfahren zur Herstellung von 2,5-substituierten Tetrahydropyran-Derivaten durch reduktive Eliminierung des entsprechenden 4-Halogen-Derivats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |